146 related articles for article (PubMed ID: 7150347)
1. Mode of action of LN 1643 (a triphenylbromoethylene antiestrogen): probable mediation by the estrogen receptor and high affinity metabolite.
Borgna JL; Coezy E; Rochefort H
Biochem Pharmacol; 1982 Oct; 31(20):3187-91. PubMed ID: 7150347
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogen pharmacology and mechanism of action.
Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
[TBL] [Abstract][Full Text] [Related]
3. Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.
Jordan VC; Gosden B
J Steroid Biochem; 1983 Sep; 19(3):1249-58. PubMed ID: 6684713
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY
Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393
[TBL] [Abstract][Full Text] [Related]
5. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
6. Interactions of antiestrogens with human breast cancer in long-term tissue culture.
Lippman M; Bolan G; Huff K
Cancer Treat Rep; 1976 Oct; 60(10):1421-9. PubMed ID: 1035504
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
10. Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxy or counterpart function with the estrogen receptor.
Borgna JL; Scali J
Eur J Biochem; 1991 Aug; 199(3):575-85. PubMed ID: 1868844
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-receptor--DNA interaction. Difference between activation by estrogen and antiestrogen.
Evans E; Baskevitch PP; Rochefort H
Eur J Biochem; 1982 Nov; 128(1):185-91. PubMed ID: 7173202
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of antiestrogens and androgens on the estrogen receptor.
Rochefort H; Capony F; Garcia M
J Steroid Biochem; 1979; 11(5-6):1635-8. PubMed ID: 574911
[No Abstract] [Full Text] [Related]
13. Triphenylethylene antiestrogen binding sites (TABS) specificity.
Clark JH; Mitchell WC; Guthrie SC
J Steroid Biochem; 1987 Apr; 26(4):433-7. PubMed ID: 3586657
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
15. Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor.
Sutherland RL; Watts CK; Ruenitz PC
Biochem Biophys Res Commun; 1986 Oct; 140(2):523-9. PubMed ID: 3778464
[TBL] [Abstract][Full Text] [Related]
16. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
17. Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity.
Hyder SM; Chiappetta C; Stancel GM
Cancer Lett; 1997 Dec; 120(2):165-71. PubMed ID: 9461033
[TBL] [Abstract][Full Text] [Related]
18. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells.
Weaver CA; Springer PA; Katzenellenbogen BS
Mol Endocrinol; 1988 Oct; 2(10):936-45. PubMed ID: 2460749
[TBL] [Abstract][Full Text] [Related]
19. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
20. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
Watts CK; Sutherland RL
Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
